Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results

BACKGROUND: Olipudase alfa is a recombinant human acid sphingomyelinase (ASM) enzyme replacement therapy (ERT) for non-central-nervous-system manifestations of acid sphingomyelinase deficiency (ASMD). We report 2-year cumulative safety and efficacy data after olipudase alfa treatment in 20 children...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, George A., Giugliani, Roberto, Guffon, Nathalie, Jones, Simon A., Mengel, Eugen, Scarpa, Maurizio, Witters, Peter, Yarramaneni, Abhimanyu, Li, Jing, Armstrong, Nicole M., Kim, Yong, Ortemann-Renon, Catherine, Kumar, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749157/
https://www.ncbi.nlm.nih.gov/pubmed/36517856
http://dx.doi.org/10.1186/s13023-022-02587-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749157/
https://www.ncbi.nlm.nih.gov/pubmed/36517856
http://dx.doi.org/10.1186/s13023-022-02587-0

Ejemplares similares